Join Growin Stock Community!

Alaunos therapeutics, inc.TCRT.US Overview

US StockHealthcare
(No presentation for TCRT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

TCRT AI Insights

TCRT Overall Performance

TCRT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

TCRT Recent Performance

-3.13%

Alaunos therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

TCRT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

TCRT Key Information

TCRT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

TCRT Profile

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.

Price of TCRT

TCRT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

TCRT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.80
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1186.59
PB Ratio
2.50
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-100625.00%
Revenue Growth (YoY)
-20.00%
Profit Growth (YoY)
-20.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.80
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1186.59
PB Ratio
2.50
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-100625.00%
Revenue Growth (YoY)
-20.00%
Profit Growth (YoY)
-20.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is TCRT's latest earnings report released?

    The most recent financial report for Alaunos therapeutics, inc. (TCRT) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TCRT's short-term business performance and financial health. For the latest updates on TCRT's earnings releases, visit this page regularly.

  • How much cash does TCRT have?

    At the end of the period, Alaunos therapeutics, inc. (TCRT) held Total Cash and Cash Equivalents of 1.94M, accounting for 0.52 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is TCRT's EPS continuing to grow?

    According to the past four quarterly reports, Alaunos therapeutics, inc. (TCRT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.55. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of TCRT?

    Alaunos therapeutics, inc. (TCRT)'s Free Cash Flow (FCF) for the period is -844K, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 8.07% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.